Drugs /

dhax regimen

Back to Drugs List

Overview

NCI Definition [1]:
A regimen consisting of dexamethasone, cytarabine and oxaliplatin that can be used to treat relapsed/refractory B-cell non-Hodgkin lymphoma (NHL).

Clinical Trials

View Clinical Trials for dhax regimen

Dhax regimen has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating dhax regimen, 1 is phase 2 (1 open).

MS4A1 Expression is the most frequent biomarker inclusion criterion for dhax regimen clinical trials.

Post-transplant lymphoproliferative disorder is the most common disease being investigated in dhax regimen clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Dhax Regimen
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating dhax regimen and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
dexamethasone/cytarabine/oxaliplatin regimen, dha-ox regimen, dhaox regimen, dha-oxaliplatin regimen
NCIT ID [1]:
C159557

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.